The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Beta-amyloid auto-antibodies are reduced in Alzheimer's disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mutations in Ankk1 are related to reductions in autoantibodies against Aβ in AD.
“Mutations in Ankk1 have been related to reductions in autoantibodies against Aβ in AD, suggesting a possible link between Ankk1 and ApoE in the pathogenesis of AD (81).”
From Lipidome and proteome of astrocyte and microglia ApoE lipoprotein reveal differences based on cell type and ApoE isoform (2026) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“Active immunization with Aβ peptide increased blood anti-Aβ antibodies and thus decreased brain Aβ plaque burden in AD mouse models (Schenk et al., 1999; Morgan et al., 2000) as well as in AD patients (Gilman et al., 2005; Holmes et al., 2008).”
BackgroundClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Britschgi, M., Olin, C. E., Johns, H. T., Takeda-Uchimura, Y., LeMieux, M. C., Rufibach, K., Rajadas, J., Zhang, H., Tomooka, B., Robinson, W. H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904866106 · Cited by 201
Flagged first, then by citations
Research works printed but not linked: 36
- Baril, 2004, Immune response to Aβ-peptides in peripheral blood from patients with Alzheimer's disease and control subjects, Neurosci. Lett., 355, 226, 10.1016/j.neulet.2003.10.071 · DOI
- Brettschneider, 2005, Decreased serum amyloid beta(1–42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radio labeled amyloid beta(1–42) peptide, Biol. Psychiatry, 57, 813, 10.1016/j.biopsych.2004.12.008 · DOI
- Corder, 1993, Pericak-Vance MAGene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, 13, 921, 10.1126/science.8346443 · DOI · Paper page
- Dodel, 2010, Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence, Drugs, 70, 513, 10.2165/11533070-000000000-00000 · DOI
- Dodel, 2011, Naturally occurring autoantibodies against {beta}-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease, J. Neurosci., 31, 5847, 10.1523/JNEUROSCI.4401-10.2011 · DOI
- Du, 2003, Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity, Brain, 126, 1935, 10.1093/brain/awg191 · DOI
- Fu, 2010, Amyloid-β immunotherapy for Alzheimer's disease, CNS Neurol. Disord. Drug Targets, 9, 197, 10.2174/187152710791012017 · DOI
- Fukumoto, 2012, High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients, FASEB J., 24, 2716, 10.1096/fj.09-150359 · DOI · Paper page
- Gruden, 2007, Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: autoantibodies to Aβ(25-35) oligomers, S100b and neurotransmitters, J. Neuroimmunol., 186, 181, 10.1016/j.jneuroim.2007.03.023 · DOI
- Gustaw, 2008, Antigen–antibody dissociation in Alzheimer disease: a novel approach to diagnosis, J. Neurochem., 106, 1350, 10.1111/j.1471-4159.2008.05477.x · DOI
- Hyman, 2001, Autoantibodies to amyloid-beta and Alzheimer's disease, Ann. Neurol., 49, 808, 10.1002/ana.1061 · DOI
- Istrin, 2006, Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide, J. Neurosci. Res., 84, 434, 10.1002/jnr.20886 · DOI
- Jellinger, 2009, Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?, Acta Neuropathol., 117, 101, 10.1007/s00401-008-0466-z · DOI · Paper page
- Jinaping, 2006, Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease, Alzheimer Dis. Assoc. Disord., 20, 127, 10.1097/00002093-200607000-00001 · DOI
- Klatka, 1996, Incorrect diagnosis of Alzheimer's disease. A clinicopathologic study, Arch. Neurol., 53, 35, 10.1001/archneur.1996.00550010045015 · DOI · Paper page
- Klaver, 2010, Measurement of anti-Aβ1–42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding, J. Neurosci. Methods, 187, 263, 10.1016/j.jneumeth.2010.01.018 · DOI
- Leduc, 2011, Function and comorbidities of apolipoprotein e in Alzheimer's disease, Int. J. Alzheimers Dis., 2011, 1
- Legleiter, 2004, Effect of different anti-Aβ antibodies on Aβ fibrillogenesis as assessed by atomic force microscopy, J. Mol. Biol., 335, 997, 10.1016/j.jmb.2003.11.019 · DOI
- Li, 2006, Low avidity and level of serum anti Aβ antibodies in Alzheimer disease, Alzheimer Dis. Assoc. Disord., 20, 127, 10.1097/00002093-200607000-00001 · DOI
- Maftei, 2013, Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients, PLoS One, 8, e68996, 10.1371/journal.pone.0068996 · DOI
- Magga, 2010, Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease, J. Neuroinflammation, 7, 90, 10.1186/1742-2094-7-90 · DOI
- Meyers, 2013, The association between DRD2/ANKK1 and genetically informed measures of alcohol use and problems, Addict. Biol., 18, 523, 10.1111/j.1369-1600.2012.00490.x · DOI
- Moir, 2005, Autoantibodies to redox-modified oligomeric Aβ are attenuated in the plasma of Alzheimer's disease patients, J. Biol. Chem., 280, 17458, 10.1074/jbc.M414176200 · DOI
- Morgan, 2000, A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, 408, 982, 10.1038/35050116 · DOI
- Nath, 2003, Autoantibodies to amyloid beta peptide (Aβ) are increased in Alzheimer's disease patients and Aβ antibodies can enhance Aβ neurotoxicity: implications for disease pathogenesis and vaccine development, Neuromolecular Med., 3, 29, 10.1385/NMM:3:1:29 · DOI
- Nicoll, 2006, Aβ species removal after Aβ42 immunization, J. Neuropathol. Exp. Neurol., 65, 1040, 10.1097/01.jnen.0000240466.10758.ce · DOI · Paper page
- Petkova, 2002, A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR, Proc. Natl. Acad. Sci. U. S. A., 99, 16742, 10.1073/pnas.262663499 · DOI
- Piazz, 2013, Anti-amyloid b autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies, Ann. Neurol., 73, 449, 10.1002/ana.23857 · DOI
- Ramos, 2009, Kinetic study of β-amyloid residue accessibility using reductive alkylation and mass spectrometry, Biotechnol. Bioeng., 104, 181, 10.1002/bit.22367 · DOI
- Roses, 1996, Apolipoprotein E alleles as risk factors in Alzheimer's disease, Annu. Rev. Med., 47, 387, 10.1146/annurev.med.47.1.387 · DOI · Paper page
- Sohn, 2009, Identification of autoantibody against beta-amyloid peptide in the serum of elderly, Front. Biosci., 14, 3879, 10.2741/3496 · DOI
- Stordce, 2010, Elevation of β-amyloid 1-42 autoantibodies in the blood of amnestic patient with mild cognitive impairment, Arch. Neurol., 67, 867
- Szabo, 2008, Natural human antibodies to amyloid beta peptide, Autoimmun. Rev., 7, 415, 10.1016/j.autrev.2008.03.007 · DOI
- Weksler, 2002, Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals, Exp. Gerontol., 37, 943, 10.1016/S0531-5565(02)00029-3 · DOI
- Yoshihara, 2008, Immunoreactivity of phage library-derived human single-chain antibodies to amyloid beta conformers in vitro, J. Biochem., 143, 475, 10.1093/jb/mvm239 · DOI
- Zuo, 2009, DRD2-related TaqIA polymorphism modulates motivation to smoke, Nicotine Tob. Res., 11, 1321, 10.1093/ntr/ntp141 · DOI
Cited by
Sorted by citations
Späni, C., Suter, T., Derungs, R., Ferretti, M. T., Welt, T., Wirth, F., Gericke, C., Nitsch, R. M., & Kulic, L. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0251-x · Cited by 88
Strickland, M. R., Wang, Z., Golden, L. R., Wang, H., Lu, P., Ren, Y., Tabor, G. T., Zhao, N., Ulrich, J. D., Han, X., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101000 · Cited by 8
Metadata
- Authors
- Qu, B.-X., Gong, Y., Moore, C., Fu, M., German, D. C., Chang, L.-Y., Rosenberg, R., & Diaz-Arrastia, R.
- ORCID
- Qu, Bao-Xi
- Venue
- Journal of Neuroimmunology
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 274
- Issue
- 1-2
- Pages
- 168-173
- ISSN
- 0165-5728
- PMC
- PMC4410718
- Cited by
- 47
- References
- 7
- Language
- en
- Funders
- P30 (AG12300)
- R01 (HD048179)
- NIDRR (H133A020526)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
